Atai advances oral psychedelic in depression

Tue, Aug 13

RT @flobrand: Grateful for your coverage of our VLS-01 Phase 1 results as well as our plans for progressing VLS-01 into a Phase 2 in TRD in…

Atai Life Sciences reported early data testing an oral form of the psychedelic DMT for treatment-resistant depression. The company is also making a version of MDMA that has a different pharmacologi...

Discover